Nautilus Bio (NAUT) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

NAUT Stock Forecast

Nautilus Bio stock forecast is as follows: an average price target of $6.00 (represents a 240.91% upside from NAUT’s last price of $1.76) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

NAUT Price Target

The average price target for Nautilus Bio (NAUT) is $6.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 240.91% upside from NAUT's last price of $1.76.

NAUT Analyst Ratings

Buy

According to 3 Wall Street analysts, Nautilus Bio's rating consensus is 'Buy'. The analyst rating breakdown for NAUT stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 1 'Hold' (33.33%), 1 'Sell' (33.33%), and 0 'Strong Sell' (0.00%).

Nautilus Bio Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jun 27, 2024	Subbu Nambi	Guggenheim	$6.00	$2.29	162.58%	240.91%

The latest Nautilus Bio stock forecast, released on Jun 27, 2024 by Subbu Nambi from Guggenheim, set a price target of $6.00, which represents a 162.58% increase from the stock price at the time of the forecast ($2.29), and a 240.91% increase from NAUT last price ($1.76).

Nautilus Bio Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$6.00
Last Closing Price	$1.76	$1.76	$1.76
Upside/Downside	-100.00%	-100.00%	240.91%

In the current month, the average price target of Nautilus Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Nautilus Bio's last price of $1.76. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	New Rating	Rating Change
Jun 27, 2024	Guggenheim	Buy	Initialise
Jun 03, 2024	Jefferies	Hold	Downgrade
Apr 26, 2022	Zacks Investment Research	Sell	Downgrade

Nautilus Bio's last stock rating was published by Guggenheim on Jun 27, 2024. The company Initialise its NAUT rating from "null" to "Buy".

Nautilus Bio Financial Forecast

Nautilus Bio Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Mar 22
Revenue	-	-	-	-	-	-	-	-	-
Avg Forecast	$2.55M	$968.75K	$156.25K	$325.00K	$153.25K	$1.83M	$391.67K	$177.00K	$166.67K
High Forecast	$2.55M	$968.75K	$156.25K	$325.00K	$154.88K	$1.83M	$391.67K	$177.00K	$166.67K
Low Forecast	$2.55M	$968.75K	$156.25K	$325.00K	$151.63K	$1.83M	$391.67K	$177.00K	$166.67K
# Analysts	1	1	1	1	4	2	2	2	1
Surprise %	-	-	-	-	-	-	-	-	-

Nautilus Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NAUT's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Nautilus Bio EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Mar 22
# Analysts	1	1	1	1	4	2	2	2	1
EBITDA	-	-	-	-	-	-	-	-	$-15.22M
Avg Forecast	-	-	-	-	-	-	-	-	$-18.07M
High Forecast	-	-	-	-	-	-	-	-	$-14.46M
Low Forecast	-	-	-	-	-	-	-	-	$-21.68M
Surprise %	-	-	-	-	-	-	-	-	0.84%

undefined analysts predict NAUT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Nautilus Bio's previous annual EBITDA (undefined) of $NaN.

Nautilus Bio Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Mar 22
# Analysts	1	1	1	1	4	2	2	2	1
Net Income	-	-	-	-	-	-	-	-	$-15.50M
Avg Forecast	$-24.65M	$-24.06M	$-22.99M	$-22.23M	$-20.20M	$-20.70M	$-20.57M	$-20.39M	$-18.72M
High Forecast	$-24.65M	$-24.06M	$-22.99M	$-18.52M	$-18.94M	$-20.70M	$-20.57M	$-20.39M	$-14.97M
Low Forecast	$-24.65M	$-24.06M	$-22.99M	$-24.70M	$-20.20M	$-20.70M	$-20.57M	$-20.39M	$-22.46M
Surprise %	-	-	-	-	-	-	-	-	0.83%

Nautilus Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NAUT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Nautilus Bio SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Mar 22
# Analysts	1	1	1	1	4	2	2	2	1
SG&A	-	-	-	-	-	-	-	-	$6.36M
Avg Forecast	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-

Nautilus Bio's average Quarter SG&A projection for Mar 24 is -, based on 2 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to NAUT last annual SG&A of $6.36M (Mar 22).

Nautilus Bio EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Mar 22
# Analysts	1	1	1	1	4	2	2	2	1
EPS	-	-	-	-	-	-	-	-	$-0.12
Avg Forecast	$-0.20	$-0.19	$-0.18	$-0.18	$-0.16	$-0.17	$-0.16	$-0.16	$-0.16
High Forecast	$-0.20	$-0.19	$-0.18	$-0.15	$-0.15	$-0.17	$-0.16	$-0.16	$-0.16
Low Forecast	$-0.20	$-0.19	$-0.18	$-0.20	$-0.16	$-0.17	$-0.16	$-0.16	$-0.16
Surprise %	-	-	-	-	-	-	-	-	0.76%

According to undefined Wall Street analysts, Nautilus Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NAUT previous annual EPS of $NaN (undefined).

Nautilus Bio Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
MOLN	Molecular Partners	$5.25	$29.00	452.38%	Buy
CCCC	C4 Therapeutics	$4.05	$20.00	393.83%	Buy
ANEB	Anebulo Pharmaceuticals	$1.31	$6.00	358.02%	Buy
IPSC	Century Therapeutics	$1.17	$5.00	327.35%	Buy
PMVP	PMV Pharmaceuticals	$1.52	$6.00	294.74%	Buy
BCAB	BioAtla	$1.31	$5.00	281.68%	Buy
DTIL	Precision BioSciences	$4.58	$15.50	238.43%	Buy
NAUT	Nautilus Bio	$1.98	$6.00	203.03%	Buy
FHTX	Foghorn Therapeutics	$5.51	$14.00	154.08%	Buy
BEAM	Beam Therapeutics	$28.58	$55.00	92.44%	Buy
CRBU	Caribou Biosciences	$1.94	$3.00	54.64%	Buy
RZLT	Rezolute	$4.44	$6.67	50.23%	Buy
RVMD	Revolution Medicines	$45.16	$65.67	45.42%	Buy
KYMR	Kymera Therapeutics	$42.30	$58.60	38.53%	Buy

NAUT Forecast FAQ

Is Nautilus Bio a good buy?

Yes, according to 3 Wall Street analysts, Nautilus Bio (NAUT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 33.33% of NAUT's total ratings.

What is NAUT's price target?

Nautilus Bio (NAUT) average price target is $6 with a range of $6 to $6, implying a 240.91% from its last price of $1.76. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Nautilus Bio stock go up soon?

According to Wall Street analysts' prediction for NAUT stock, the company can go up by 240.91% (from the last price of $1.76 to the average price target of $6), up by 240.91% based on the highest stock price target, and up by 240.91% based on the lowest stock price target.

Can Nautilus Bio stock reach $3?

NAUT's average twelve months analyst stock price target of $6 supports the claim that Nautilus Bio can reach $3 in the near future.

What are Nautilus Bio's analysts' financial forecasts?

Nautilus Bio's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2.56M (high $2.56M, low $2.55M), average EBITDA is $0 (high $0, low $0), average net income is $-81.86M (high $-80.598M, low $-81.86M), average SG&A $0 (high $0, low $0), and average EPS is $-0.653 (high $-0.642, low $-0.653). NAUT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $4M (high $4M, low $4M), average EBITDA is $0 (high $0, low $0), average net income is $-93.929M (high $-90.224M, low $-96.399M), average SG&A $0 (high $0, low $0), and average EPS is $-0.749 (high $-0.719, low $-0.768).